ORGANOGENESIS HOLDINGS INC. Proceeds from Issuance of Convertible Preferred Stock
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Proceeds from Issuance of Convertible Preferred Stock of $120.69 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. proceeds from issuance of convertible preferred stock for fiscal 2024 was $120.69M.
- ORGANOGENESIS HOLDINGS INC. proceeds from issuance of convertible preferred stock for fiscal 2023 was $0.00.
- ORGANOGENESIS HOLDINGS INC. proceeds from issuance of convertible preferred stock for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|
| 2024-12-31 | $120.69M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |